01177 中國生物製藥
按盘价 
5.890 +0.070 (+1.203%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | 3.314% | 5.426% | 3.653% | 4.083% | 27.114% |
| 股东资金回报率 (%) | 7.483% | 11.211% | 7.745% | 8.473% | 62.113% |
| 资本运用回报率 (%) | 4.612% | 7.633% | 5.688% | 5.792% | 32.321% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 82.071% | 81.514% | 80.954% | 79.863% | 80.150% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 24.976% | 22.561% | 27.059% | 25.073% | 22.638% |
| 税前边际利润率 (%) | 21.811% | 18.283% | 20.649% | 20.078% | 69.143% |
| 纯利率 (%) | 7.361% | 12.124% | 8.901% | 8.838% | 54.384% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 1.368 X | 1.262 X | 1.053 X | 1.287 X | 1.532 X |
| 速动比率 (X) | 1.278 X | 1.141 X | 0.965 X | 1.171 X | 1.405 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 44.631% | 34.604% | 39.989% | 40.773% | 37.683% |
| 总债项 / 总资产比率 (%) | 21.142% | 14.846% | 19.779% | 21.825% | 20.015% |
| 净债项 / 总资产比率 (%) | 5.117% | 0.216% | 4.918% | 2.990% | 2.558% |
| 总债项 / 股东资金比率 (%) | 52.395% | 30.383% | 41.281% | 47.003% | 40.004% |
| 长期债项 / 股东资金比率 (%) | 24.946% | 6.508% | 4.505% | 14.314% | 18.264% |
| 净债项 / 股东资金比率 (%) | 12.681% | 0.441% | 10.266% | 6.440% | 5.113% |
| 净现金 / (债项) ($) | (38.89亿) | (1.41亿) | (31.28亿) | (19.16亿) | (15.49亿) |
| 每股净现金 / (债项) ($) | (0.207) | (0.008) | (0.166) | (0.102) | (0.082) |
| 总债项 / 资本运用比率 (%) | 31.627% | 21.178% | 30.685% | 31.840% | 26.810% |
| 利息盈利率 (X) | 25.948 X | 18.883 X | 11.924 X | 14.161 X | 61.180 X |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 148.034日 | 149.339日 | 158.085日 | 134.354日 | 130.670日 |
| 应收贸易帐周转率日数 (日) | 64.386日 | 59.921日 | 63.727日 | 56.176日 | 48.474日 |
| 应付贸易帐周转率日数 (日) | 17.168日 | 17.906日 | 20.703日 | 21.119日 | 24.737日 |
| 备注： | 实时报价更新时间为27/03/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 2,343,348 |
| 增长率 | -33.044% |
| 每股盈利/(亏损) | RMB 0.130 |
| 每股账面资产净值 (¥) | RMB 1.635 |